VL422 is a novel ionizable cationic lipid, as a high-performance "molecular engine" for next-generation Lipid Nanoparticles (LNPs), specifically engineered for the precise delivery of CRISPR base editors and mRNA. Its sophisticated chemical architecture is designed to remain neutral in systemic circulation for enhanced safety, while rapidly protonating within the acidic cellular environment to trigger efficient endosomal escape and cargo release. Validated by groundbreaking research in liver-targeted gene silencing, VL422 has become a critical benchmark molecule for developing permanent, transformative therapies for cardiovascular and metabolic diseases.
